Nexmed - Best Pharma Stocks of 2007

Company: Nexmed
Starting stock price: $0.72
Ending stock price: $1.42
Percent Change: 97.22%

Details: Nexmed is using NexACT--it's transdermal drug delivery technology--to create therapies that can be delivered directly through the skin. The company is developing treatments for sexual disorders and nail fungus. In 2007 Nexmed completed patient enrollment in two Phase III studies for it's anti-fungal product, and filed an NDA for an erectile dysfunction treatment.

More News:
NexMed taps Berman as new CEO. Report

Nexmed - Best Pharma Stocks of 2007
Read more on

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.